Cargando…

Specific safety and tolerability considerations in the use of anticonvulsant medications in children

Epilepsy is one of the most common neurological disorders in the pediatric age range, and the majority of affected children can be safely and effectively treated with antiepileptic medication. While there are many antiepileptic agents on the market, specific drugs may be more efficacious for certain...

Descripción completa

Detalles Bibliográficos
Autores principales: Crepeau, Amy Z, Moseley, Brian D, Wirrell, Elaine C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392695/
https://www.ncbi.nlm.nih.gov/pubmed/22792008
http://dx.doi.org/10.2147/DHPS.S28821
_version_ 1782237629080666112
author Crepeau, Amy Z
Moseley, Brian D
Wirrell, Elaine C
author_facet Crepeau, Amy Z
Moseley, Brian D
Wirrell, Elaine C
author_sort Crepeau, Amy Z
collection PubMed
description Epilepsy is one of the most common neurological disorders in the pediatric age range, and the majority of affected children can be safely and effectively treated with antiepileptic medication. While there are many antiepileptic agents on the market, specific drugs may be more efficacious for certain seizure types or electroclinical syndromes. Furthermore, certain adverse effects are more common with specific classes of medication. Additionally patient-specific factors, such as age, race, other medical conditions, or concurrent medication use may result in higher rates of side effects or altered efficacy. Significant developmental changes in gastric absorption, protein binding, hepatic metabolism, and renal clearance are seen over the pediatric age range, which impact pharmacokinetics. Such changes must be considered to determine optimal dosing and dosing intervals for children at specific ages. Furthermore, approximately one third of children require polytherapy for seizure control, and many more take concurrent medications for other conditions. In such children, drug–drug interactions must be considered to minimize adverse effects and improve efficacy. This review will address issues of antiepileptic drug efficacy, tolerability and ease of use, pharmacokinetics, and drug–drug interactions in the pediatric age range.
format Online
Article
Text
id pubmed-3392695
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-33926952012-07-12 Specific safety and tolerability considerations in the use of anticonvulsant medications in children Crepeau, Amy Z Moseley, Brian D Wirrell, Elaine C Drug Healthc Patient Saf Review Epilepsy is one of the most common neurological disorders in the pediatric age range, and the majority of affected children can be safely and effectively treated with antiepileptic medication. While there are many antiepileptic agents on the market, specific drugs may be more efficacious for certain seizure types or electroclinical syndromes. Furthermore, certain adverse effects are more common with specific classes of medication. Additionally patient-specific factors, such as age, race, other medical conditions, or concurrent medication use may result in higher rates of side effects or altered efficacy. Significant developmental changes in gastric absorption, protein binding, hepatic metabolism, and renal clearance are seen over the pediatric age range, which impact pharmacokinetics. Such changes must be considered to determine optimal dosing and dosing intervals for children at specific ages. Furthermore, approximately one third of children require polytherapy for seizure control, and many more take concurrent medications for other conditions. In such children, drug–drug interactions must be considered to minimize adverse effects and improve efficacy. This review will address issues of antiepileptic drug efficacy, tolerability and ease of use, pharmacokinetics, and drug–drug interactions in the pediatric age range. Dove Medical Press 2012-06-06 /pmc/articles/PMC3392695/ /pubmed/22792008 http://dx.doi.org/10.2147/DHPS.S28821 Text en © 2012 Crepeau et al, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Crepeau, Amy Z
Moseley, Brian D
Wirrell, Elaine C
Specific safety and tolerability considerations in the use of anticonvulsant medications in children
title Specific safety and tolerability considerations in the use of anticonvulsant medications in children
title_full Specific safety and tolerability considerations in the use of anticonvulsant medications in children
title_fullStr Specific safety and tolerability considerations in the use of anticonvulsant medications in children
title_full_unstemmed Specific safety and tolerability considerations in the use of anticonvulsant medications in children
title_short Specific safety and tolerability considerations in the use of anticonvulsant medications in children
title_sort specific safety and tolerability considerations in the use of anticonvulsant medications in children
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392695/
https://www.ncbi.nlm.nih.gov/pubmed/22792008
http://dx.doi.org/10.2147/DHPS.S28821
work_keys_str_mv AT crepeauamyz specificsafetyandtolerabilityconsiderationsintheuseofanticonvulsantmedicationsinchildren
AT moseleybriand specificsafetyandtolerabilityconsiderationsintheuseofanticonvulsantmedicationsinchildren
AT wirrellelainec specificsafetyandtolerabilityconsiderationsintheuseofanticonvulsantmedicationsinchildren